新型小分子药物治疗炎症性肠病的研究进展

刘 国武1, 刘 慧敏1, 童明 富*2
1、赣南医科大学第一临床医学院;九江学院附属医院
2、九江学院附属医院

摘要


炎症性肠病（IBD）是一类病因尚不明确的慢性肠道炎症疾病，具有病程长、易复发且迁延不愈等特点，严
重影响患者生活质量。目前，IBD的传统治疗药物包括如氨基水杨酸类药物、免疫抑制剂、激素等，但因其安全和
疗效性等问题逐渐。近年来，抗肿瘤坏死因子α、整合素α4β7、白介素IL-12/23等生物制剂应用越来越广泛，但
因其安全性问题和失应答率较高且安全性较低等缺陷，导致其临床应用受到限制。随着JAK抑制剂乌帕替尼在国内
外成功获批使用于临床治疗中重度溃疡性结肠炎，小分子药物在IBD治疗领域中受到极大关注，它可能为IBD患者
提供有效的补充治疗。本文就近年来治疗炎症性肠病的小分子药物研究进展进行综述，旨在了解本领域的最新进展。

关键词


小分子药物；炎症性肠病；克罗恩病；溃疡性结肠炎；研究进展

全文:

PDF


参考


[1]RODA G, CHIEN NG S, KOTZE P G, 等 .

Crohn’s disease[J/OL]. Nature Reviews. Disease Primers,

2020, 6(1): 22. DOI:10.1038/s41572-020-0156-2.

[2]UNGARO R, MEHANDRU S, ALLEN P B,

等 . Ulcerative colitis[J/OL]. Lancet (London, England),

2017, 389(10080): 1756-1770. DOI:10.1016/S0140-

6736(16)32126-2.

[3]KAPLAN G G, WINDSOR J W. The four

epidemiological stages in the global evolution of inflammatory

bowel disease[J/OL]. Nature Reviews. Gastroenterology &

Hepatology, 2021, 18(1): 56-66. DOI:10.1038/s41575-020-

00360-x.

[4]RODA G, JHARAP B, NEERAJ N, 等 . Loss

of Response to Anti-TNFs: Definition, Epidemiology,

and Management[J/OL]. Clinical and Translational

Gastroenterology, 2016, 7(1): e135. DOI:10.1038/

ctg.2015.63.

[5]SIEGEL C A, FINLAYSON S R G, SANDS B E,

等. Adverse events do not outweigh benefits of combination

therapy for Crohn’s disease in a decision analytic model[J/

OL]. Clinical Gastroenterology and Hepatology: The Official

Clinical Practice Journal of the American Gastroenterological

Association, 2012, 10(1): 46-51. DOI:10.1016/

j.cgh.2011.09.017.

[6]BEAUGERIE L, BROUSSE N, BOUVIER A

M, 等. Lymphoproliferative disorders in patients receiving

thiopurines for inflammatory bowel disease: a prospective

observational cohort study[J/OL]. Lancet (London, England),

2009, 374(9701): 1617-1625. DOI:10.1016/S0140-

6736(09)61302-7.

[7]OH N, JB S, M A, 等. Will novel oral formulations

change the management of inflammatory bowel disease?[J/

OL]. Expert opinion on investigational drugs, 2016, 25(6)

[2023-01-14]. https://pubmed.ncbi.nlm.nih.gov/26967267/.

DOI:10.1517/13543784.2016.1165204.

[8]DM M, MI J, X L, 等 . Anti-inflammatory

activity and neutrophil reductions mediated by the JAK1/

JAK3 inhibitor, CP-690,550, in rat adjuvant-induced

arthritis[J/OL]. Journal of inflammation (London, England),

2010, 7[2023-01-14]. https://pubmed.ncbi.nlm.nih.

gov/20701804/. DOI:10.1186/1476-9255-7-41.

[9]VARYANI F, ARGYRIOU K, PHILLIPS F, 等.

Profile of Tofacitinib in the Treatment of Ulcerative Colitis:

An Evidence-Based Review of Recent Data[J/OL]. Drug

Design, Development and Therapy, 2019, 13: 4091-4105.

DOI:10.2147/DDDT.S182891.

[10]SANDBORN W J, SU C, SANDS B E, 等 .

Tofacitinib as Induction and Maintenance Therapy for

Ulcerative Colitis[J/OL]. The New England Journal of

Medicine, 2017, 376(18): 1723-1736. DOI:10.1056/

NEJMoa1606910.

[ 1 1 ] J E A N - F R E D E R I C C , W A L T E R R ,

OSTERMAN M T, 等. Maintenance of Remission with

Tofacitinib in Patients With Ulcerative Colitis: Subpopulation

Analysis from an Open-Label, Long-Term Extension

Study: P-015[J]. Official journal of the American College of

Gastroenterology | ACG, 2018, 113: S4.

[12]HANAUER S, PANACCIONE R, DANESE

S, 等. Tofacitinib Induction Therapy Reduces Symptoms

Within 3 Days for Patients With Ulcerative Colitis[J/OL].

Clinical Gastroenterology and Hepatology: The Official

Clinical Practice Journal of the American Gastroenterological

Association, 2019, 17(1): 139-147. DOI:10.1016/

j.cgh.2018.07.009.

[13]SANDBORN W J, GHOSH S, PANES J,

等 . A phase 2 study of tofacitinib, an oral Janus kinase

inhibitor, in patients with Crohn’s disease[J/OL]. Clinical

Gastroenterology and Hepatology: The Official Clinical

Practice Journal of the American Gastroenterological

Association, 2014, 12(9): 1485-1493.e2. DOI:10.1016/

j.cgh.2014.01.029.

[14]FEAGAN B G, DANESE S, LOFTUS E V,

等 . Filgotinib as induction and maintenance therapy for

ulcerative colitis (SELECTION): a phase 2b/3 double-blind,

randomised, placebo-controlled trial[J/OL]. Lancet (London,

England), 2021, 397(10292): 2372-2384. DOI:10.1016/

S0140-6736(21)00666-8.

[15]VERMEIRE S, SCHREIBER S, PETRYKA R,

等. Clinical remission in patients with moderate-to-severe

Crohn’s disease treated with filgotinib (the FITZROY

study): results from a phase 2, double-blind, randomised,

placebo-controlled trial[J/OL]. Lancet (London, England),

2017, 389(10066): 266-275. DOI:10.1016/S0140-

6736(16)32537-5.

[16]DANESE S, VERMEIRE S, ZHOU W, 等 .

OP24 Efficacy and safety of upadacitinib induction therapy

in patients with Moderately to Severely Active Ulcerative

Colitis: Results from the phase 3 U-ACHIEVE study[J/OL].

Journal of Crohn’s and Colitis, 2021, 15(Supplement_1):

S022-S024. DOI:10.1093/ecco-jcc/jjab075.023.

[17]SANDBORN W J, GHOSH S, PANES J, 等 .

Efficacy of Upadacitinib in a Randomized Trial of Patients

With Active Ulcerative Colitis[J/OL]. Gastroenterology,

2020, 158(8): 2139-2149.e14. DOI:10.1053/

j.gastro.2020.02.030.

[18]D’HAENS G, PANÉS J, LOUIS E, 等 .

Upadacitinib Was Efficacious and Well-tolerated Over 30

Months in Patients With Crohn’s Disease in the CELEST

Extension Study[J/OL]. Clinical Gastroenterology and

Hepatology: The Official Clinical Practice Journal of the

American Gastroenterological Association, 2022, 20(10):

2337-2346.e3. DOI:10.1016/j.cgh.2021.12.030.

[19]SANDBORN W J, FEAGAN B G, PANES J, 等.

Safety and Efficacy of ABT-494 (Upadacitinib), an Oral Jak1

Inhibitor, as Induction Therapy in Patients with Crohn’s

Disease: Results from Celest[J/OL]. Gastroenterology,

2017, 152(5): S1308-S1309. DOI:10.1016/S0016-

5085(17)34357-3.

[20]SANDS B E, SANDBORN W J, FEAGAN B G,

等. Peficitinib, an Oral Janus Kinase Inhibitor, in Moderateto-severe Ulcerative Colitis: Results From a Randomised,

Phase 2 Study[J/OL]. Journal of Crohn’s & Colitis, 2018,

12(10): 1158-1169. DOI:10.1093/ecco-jcc/jjy085.

[21]D’AMICO F, PEYRIN-BIROULET L,

DANESE S, 等. New drugs in the pipeline for the treatment

of inflammatory bowel diseases: what is coming?[J/OL].

Current Opinion in Pharmacology, 2020, 55: 141-150.

DOI:10.1016/j.coph.2020.10.015.

[22]YOSHIMURA N, WATANABE M, MOTOYA

S, 等. Safety and Efficacy of AJM300, an Oral Antagonist of

α4 Integrin, in Induction Therapy for Patients With Active

Ulcerative Colitis[J/OL]. Gastroenterology, 2015, 149(7):

1775-1783.e2. DOI:10.1053/j.gastro.2015.08.044.

[23]TAKAZOE M, WATANABE M, KAWAGUCHI

T. Oral Alpha-4 Integrin Inhibitor (AJM300) in Patients with

Active Crohn’s Disease — A Randomized, Double-Blind,

Placebo-Controlled Trial[EB].

[24]SANDBORN W J, MATTHEAKIS L C, MODI

N B, 等. PTG-100, an Oral α4β7 Antagonist Peptide:

Preclinical Development and Phase 1 and 2a Studies in

Ulcerative Colitis[J/OL]. Gastroenterology, 2021, 161(6):

1853-1864.e10. DOI:10.1053/j.gastro.2021.08.045.

[25]PEYRIN-BIROULET L, CHRISTOPHER R,

BEHAN D, 等. Modulation of sphingosine-1-phosphate in

inflammatory bowel disease[J/OL]. Autoimmunity Reviews,

2017, 16(5): 495-503. DOI:10.1016/j.autrev.2017.03.007.

[26]TSAI H C, HAN M H. Sphingosine-1-Phosphate

(S1P) and S1P Signaling Pathway: Therapeutic Targets in

Autoimmunity and Inflammation[J/OL]. Drugs, 2016, 76(11):

1067-1079. DOI:10.1007/s40265-016-0603-2.

[27]SANDBORN W J, PEYRIN-BIROULET L,

ZHANG J, 等. Efficacy and Safety of Etrasimod in a Phase 2

Randomized Trial of Patients With Ulcerative Colitis[J/OL].

Gastroenterology, 2020, 158(3): 550-561. DOI:10.1053/

j.gastro.2019.10.035.

[28]VERMEIRE S, CHIOREAN M, PANÉS J, 等.

Long-term Safety and Efficacy of Etrasimod for Ulcerative

Colitis: Results from the Open-label Extension of the OASIS

Study[J/OL]. Journal of Crohn’s and Colitis, 2021, 15(6):

950-959. DOI:10.1093/ecco-jcc/jjab016.

[29]SANDBORN W J, VERMEIRE S, PEYRINBIROULET L, 等. Etrasimod 2 mg Once Daily as Treatment

for Moderately to Severely Active Ulcerative Colitis: Results

From the Phase 3 ELEVATE UC 52 and ELEVATE UC 12

Trials[J].

[30]SANDBORN W J, FEAGAN B G, WOLF D

C, 等. Ozanimod Induction and Maintenance Treatment

for Ulcerative Colitis[J/OL]. The New England Journal

of Medicine, 2016, 374(18): 1754-1762. DOI:10.1056/

NEJMoa1513248.

[31]FEAGAN B G, SANDBORN W J, DANESE S,

等. Ozanimod induction therapy for patients with moderate

to severe Crohn’s disease: a single-arm, phase 2, prospective

observer-blinded endpoint study[J/OL]. The Lancet.

Gastroenterology & Hepatology, 2020, 5(9): 819-828.

DOI:10.1016/S2468-1253(20)30188-6.

[32]KAPPOS L, ARNOLD D L, BAR-OR A, 等.

Safety and efficacy of amiselimod in relapsing multiple sclerosis

(MOMENTUM): a randomised, double-blind, placebocontrolled phase 2 trial[J/OL]. The Lancet Neurology, 2016,

15(11): 1148-1159. DOI:10.1016/S1474-4422(16)30192-2.

[33]SHIMANO K, MAEDA Y, KATAOKA H, 等.

Amiselimod (MT-1303), a novel sphingosine 1-phosphate

receptor-1 functional antagonist, inhibits progress of chronic

colitis induced by transfer of CD4+CD45RBhigh T cells[J/

OL]. PloS One, 2019, 14(12): e0226154. DOI:10.1371/

journal.pone.0226154.

[34]D’HAENS G, DANESE S, DAVIES M, 等. A

phase II, Multicentre, Randomised, Double-Blind, Placebocontrolled Study to Evaluate Safety, Tolerability, and Efficacy

of Amiselimod in Patients with Moderate to Severe Active

Crohn’s Disease[J/OL]. Journal of Crohn’s & Colitis,

2022, 16(5): 746-756. DOI:10.1093/ecco-jcc/jjab201.

[ 3 5 ] M I T S U B I S H I T A N A B E P H A R M A

CORPORATION. A Phase II, Open-label, Multicentre

Study to Evaluate the Long-term Safety and Efficacy of MT-

1303 in Subjects With Moderate to Severe Active Crohn’s

Disease Who Have Completed the MT 1303-E13 Study:

NCT02389790[R/OL]. clinicaltrials.gov, 2017[2023-03-05].

https://clinicaltrials.gov/ct2/show/NCT02389790.

[36]DANIEL C, SARTORY N, ZAHN N, 等 .

FTY720 ameliorates Th1-mediated colitis in mice by

directly affecting the functional activity of CD4+CD25+

regulatory T cells[J/OL]. Journal of Immunology (Baltimore,

Md.: 1950), 2007, 178(4): 2458-2468. DOI:10.4049/

jimmunol.178.4.2458.

[37]VERSTOCKT B, VETRANO S, SALAS A, 等.

Sphingosine 1-phosphate modulation and immune cell

trafficking in inflammatory bowel disease[J/OL]. Nature

Reviews Gastroenterology & Hepatology, 2022, 19(6): 351-

366. DOI:10.1038/s41575-021-00574-7.

[38]VARGAS W S, PERUMAL J S. Fingolimod and

cardiac risk: latest findings and clinical implications[J/OL].

Therapeutic Advances in Drug Safety, 2013, 4(3): 119-124.

DOI:10.1177/2042098613481023.

[39]林俊超，梁洁，吴开春.生物制剂与小分子药物

在炎症性肠病治疗中的进展[J].中国医学前沿杂志（电子

版），2021，13（7）：6-13.

[40]D’HAENS G, SANDBORN W J, COLOMBEL J

F, 等. A phase II study of laquinimod in Crohn’s disease[J/

OL]. Gut, 2015, 64(8): 1227-1235. DOI:10.1136/gutjnl-

2014-307118.

[41]SPADACCINI M, D’ALESSIO S, PEYRINBIROULET L, 等 . PDE4 Inhibition and Inflammatory

Bowel Disease: A Novel Therapeutic Avenue[J/OL].

International Journal of Molecular Sciences, 2017, 18(6):

1276. DOI:10.3390/ijms18061276.

[42]STRIK A, LÖWENBERG M, PONSIOEN C, 等.

OP005 Higher anti-TNF serum levels are associated with

perianal fistula closure in Crohn’s disease patients[J]. 2018.

[43]DANESE S, NEURATH M F, KOPOŃ A, 等.

Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase

4, in a Randomized Trial of Patients With Active Ulcerative

Colitis[J/OL]. Clinical Gastroenterology and Hepatology:

The Official Clinical Practice Journal of the American

Gastroenterological Association, 2020, 18(11): 2526-2534.e9.

DOI:10.1016/j.cgh.2019.12.032.


Refbacks

  • 当前没有refback。